Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab-trastuzumab plus letrozole in endocrine-sensitive HER2-positive breast cancer (phase II neoadjuvant)
2013-002662-40Phase 2Completed
- Sponsor
- Astrocyte Pharmaceuticals Inc.
- Start
- Jul 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab, trastuzumab and letrozole in breast cancer, sponsored by Astrocyte Pharmaceuticals Inc. Primary endpoint: Pathologic complete response in breast and axillary nodes. Started Jul 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-002662-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002662-40.